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Regulators of G protein signalling (RGS) proteins were
first found to limit heterotrimer G protein signalling
by accelerating the hydrolysis of GTP-bound to Ga
subunits, thereby terminating receptor pathway sig-
nalling. Subsequently, RGS proteins have been found
to act as scaffolding proteins, to interact directly and
selectively to G protein-coupled receptors (GPCRs)
and to act as effector modulators (Ghavami et al. 2004;
McCoy & Hepler, 2009). Through all of these interac-
tions, RGS proteins act to negatively regulate signal-
ling pathways. The selective interactions that occur
among GPCRs, G proteins and RGS proteins provide
an opportunity for more selective drug targeting
to a specific complex of these proteins, (McCoy &
Hepler, 2009 ; Shankaranarayanan et al. 2008) rather
than the traditional approach of targeting GPCRs
or more recent proposals for targeting RGS proteins.
Targeting select GPCR/G protein/RGS complexes
may prove useful for improving the treatment of
depression.
Although major depression is a common disorder,
treatment approaches for depression are woefully in-
adequate (Insel & Wang, 2009). Approximately one in
six people in the USA suffer from major depressive
disorder and individuals have a 16.2% lifetime
prevalence for depression (Kessler et al. 2003). There
are several classes of medications which are useful
in the treatment of depression including selective
serotonin reuptake inhibitors (SSRIs) and mixed
norepinephrine/serotonin reuptake inhibitors. In fact,
from recently published data on the top prescription
drugs of 2010, two of these reuptake inhibitor anti-
depressants, escitalopram and duloxetine (Lindsley,
2011) are in the top 20 in sales in the USA. Despite
the widespread use of antidepressant medications
and especially reuptake inhibitors, there is a pressing
need for better treatments for depression (Insel &
Wang, 2009). The results from a major, large-scale
clinical study, the Sequenced Treatment Alternatives
to Relieve Depression trial emphasize three major
problems with current antidepressant therapy. First,
the current medications do not alleviate depression for
a large percentage of patients. Second, when patients
do respond to the medications, it takes weeks of
therapy not hours or days as with most medications.
Third, patients may respond to one antidepressant
medication or combination of medications but not
others and currently there are not methods to predict
which medication or combination of medications will
be effective for any individual (Insel & Wang, 2009 ;
Kessler et al. 2003). It is therefore essential to identify
new targets and new therapeutic approaches for the
treatment of depression.
The paper ‘Relationship between Rgs2 gene ex-
pression levels and anxiety and depression-like
behaviour in a mutant mouse model : serotonergic in-
volvement’ by Lifschytz et al. (2011) brings to our
attention the importance of RGS protein modulation
of receptor signalling in anxiety and depression. In
their study, mice carrying a mutation in the RGS2
gene causing reduced expression levels were exam-
ined in several tests for anxiety and depressive–like
behaviours. Mice homozygous for the RGS2 mutation
demonstrated increased depressive-like behaviour
while both heterozygotes and homozygotes displayed
increased anxiety-like behaviours and reduced socia-
bility. Linking their results to serotonin (5-HT)1A
receptor signalling was accomplished by demon-
strating that the RGS2 mutant mice have reduced
hypothermic responses to the 5-HT1A/7 receptor agon-
ist, 8-hydroxy-2-dipropylaminotetralin (DPAT). The
reduced hypothermic responses suggest that RGS2
is an important modulator of 5-HT1A autoreceptor
function in the raphe nucleus (Richardson-Jones et al.
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2010). Furthermore, 5-HT1A and 5-HT1B mRNA ex-
pression levels were reduced in the raphe nucleus
of the RGS2 mutant mice. 5-HT1B and especially
5-HT1A receptor signalling have a strong association
with depression and anxiety and their treatments.
It is important to note that RGS2 also modulates Gq/11
coupled receptor signalling such as 5-HT2A/2C, sig-
nalling pathways (McCoy & Hepler, 2009) which
play a major role in depression and anxiety-like
behaviours. Furthermore, previous studies have dem-
onstrated that depression and anxiety-related neuro-
psychiatric disorders are linked to several single
nucleotide polymorphisms (SNPs) in the RGS2 gene,
one of which resulted in lower expression of RGS2
protein (Semplicini et al. 2006).
Recent reports suggest that 5-HT1A receptors couple
to different Ga protein subunits and RGS proteins in
other brain regions such as to Gaz/RGSZ1 in the
hypothalamus to regulate neuroendocrine responses
to DPAT (Serres et al. 2000) and to Gai2 in the hippo-
campus and cortex (Talbot et al. 2010). 5-HT1A receptor
signalling in each of these brain regions and signalling
pathway complexes impacts on depression. Altered
RGSZ1 expression in the hypothalamus may acceler-
ate adaptive responses to treatment with SSRIs and
thereby hasten the onset of antidepressant responses
(Carrasco et al. 2004 ; Estrada-Camarena et al. 2006a, b).
Drug development to selectively target particular
5-HT1A receptor/Ga/RGS protein complexes may
provide an opportunity to selectively impact on a
particular 5-HT1A receptor pathway. Studies such as
the one by Lifschytz et al. (2011) provide important
underpinnings for the development of this type of
selective targeting for the treatment for depression
to provide relief for the large number of patients re-
fractory to current therapeutic approaches and to
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